NCT06900647View on ClinicalTrials.gov

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Metastatic Breast CancerRecurrent Breast Cancer
Interventions
DRUG

Bortezomib (B)

1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Cisplatin (CDDP)

50mg/m2, IV, D1-3, every 3 weeks

DRUG

Bortezomib (B)

1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Bortezomib (B)

1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Cisplatin (CDDP)

70mg/m2, IV, D1-3, every 3 weeks

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER